Comparative Pharmacology
Head-to-head clinical analysis: SULFAMYLON versus SULFAPYRIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMYLON versus SULFAPYRIDINE.
SULFAMYLON vs SULFAPYRIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamylon (mafenide acetate) is a synthetic sulfonamide that exerts bacteriostatic activity against a wide range of Gram-negative and Gram-positive organisms. It acts by inhibiting the enzyme dihydropteroate synthase, which is involved in folate synthesis, thereby blocking bacterial DNA replication. Additionally, it may be bactericidal at high concentrations via inhibition of cell wall synthesis.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
Topical: Apply a thin layer to the wound once or twice daily. Maximum coverage area should not exceed body surface area of 20%.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
None Documented
None Documented
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
The terminal elimination half-life is approximately 7-8 hours in patients with normal renal function. In renal impairment, half-life may be prolonged, requiring dosing adjustments.
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Primarily renal excretion as unchanged drug and its metabolite; approximately 87% of a dose is recovered in urine within 24 hours as sulfacetamide and its deacetylated metabolite, with about 10% as unchanged drug. Less than 2% is excreted in feces.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic